European Leukemia Trial Registry
Trial: CLBH589X2106

More Details
Title Panobinostat and Ruxolitinib in PMF, PPV-MF or PET-MF
Scientific Title A Phase 1b, Open-label, Multi-center, Single Arm, Dose Finding Study to Assess Safety and Pharmacokinetics of the Oral Combination of Panobinostat and Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-polycythemia Vera-myelofibrosis (PPV-MF) or Post-essential Thrombocythemia-myelofibrosis (PET-MF).
Short Title CLBH589X2106
Trialgroup NN
Type of Trial multicentric, single-group, open-label
Disease Myeloproliferative disease(MPD) Myelofibrosis
Age >= 18 years
Status No longer recruiting
Start of Recruitment 01.01.2014
Shortprotocol Shortprotocol
created 17.01.2014 Hanna Ebert
changed 08.06.2015 Hanna Ebert
ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | |